PRR30: A Potential Drug Target and Biomarker (G339779)

Target Name: PRR30

NCBI ID: G339779

PRR30

Other Name(s): proline rich 30 | C2orf53 | Proline-rich protein 30 | PRR30_HUMAN | Proline rich 30

PRR30: A Potential Drug Target and Biomarker

Proline-rich repeat (PRR) genes are a family of non-coding RNAs that have been identified as key regulators of various cellular processes. PRRs are involved in the regulation of protein synthesis, cell signaling, and DNA replication. The PRR30 gene is one of the PRR genes that has been well-studied, and its function in cellular processes is still poorly understood.

The PRR30 gene is located at chromosome 18q21 and has 29 exons. It encodes a protein named Prr30, which is a 30-kDa protein that contains a unique N-terminus and a C-terminus. The N-terminus of Prr30 contains a highly conserved region that is involved in protein-protein interactions, while the C-terminus contains a unique region that is involved in the regulation of protein translation.

Studies have shown that Prr30 is involved in various cellular processes, including cell signaling, protein synthesis, and DNA replication. It has been shown to play a role in the regulation of cell adhesion, migration, and invasion. It has also been shown to be involved in the regulation of neurotransmitter release and sensitivity to pain.

In addition to its involvement in cellular processes, Prr30 has also been shown to be a potential drug target. The high degree of conservation between the N-terminus and C-terminus of Prr30 makes it a promising target for small molecules. Several studies have shown that inhibitors of Prr30 can suppress the activity of various cellular signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

Furthermore, recent studies have shown that Prr30 can also be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The expression of Prr30 has been shown to be elevated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, PRR30 is a well-studied gene that has been shown to be involved in various cellular processes and has been identified as a potential drug target. Its unique N-terminus and C-terminus, as well as its conservation in various species, make it a promising target for small molecules. Furthermore, its involvement in various diseases makes it a valuable biomarker for the diagnosis and treatment of these diseases. Further research is needed to fully understand the function of PRR30 and its potential as a drug target and biomarker.

Protein Name: Proline Rich 30

The "PRR30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRR30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets